| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -0.9 | -2.8 |
| Net income | -0.9 | -2.8 |
| EPS (diluted, $ a share) | $-0.14 | $-2.50 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: QCLS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Q/C Technologies, Inc.: key numbers
- Share price
- $0.3210Close, Nov 16
- Market cap
- $2.77M
- Shares outstanding
- 8.62MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Q/C Technologies, Inc.
All →Q/C Technologies Nasdaq/NYSE Compliance Notice
Q/C Technologies received a deficiency notice from Nasdaq on November 6, 2026, because its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, or until May 5, 2027, to regain compliance with the minimum bid price requirement. If compliance is not regained, the company may be eligible for an additional 180-day period or face delisting.
- Counterparty
- Nasdaq
- Term
- 180 days
Q/C Technologies Executive Compensation
Q/C Technologies appointed Dr. Yossef Ehrlichman as Chief Technology Officer and entered into an amended employment agreement. The agreement includes an annual base salary of $275,000 and a restricted stock award with a grant date fair market value of $250,000, subject to stockholder approval of a share reserve increase. Dr. Ehrlichman previously served as the company's Founding Manager of Photonic Integrated Circuit Development.
- Counterparty
- Yossef Ehrlichman
- Term
- at-will